Generali Investments Management Co LLC Boosts Stock Position in Boston Scientific Co. (NYSE:BSX)

Generali Investments Management Co LLC increased its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 14.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,912 shares of the medical equipment provider's stock after acquiring an additional 3,886 shares during the period. Boston Scientific comprises 0.9% of Generali Investments Management Co LLC's holdings, making the stock its 29th largest position. Generali Investments Management Co LLC's holdings in Boston Scientific were worth $3,118,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new stake in shares of Boston Scientific during the 4th quarter valued at about $33,074,000. DAVENPORT & Co LLC increased its stake in shares of Boston Scientific by 5.0% in the 4th quarter. DAVENPORT & Co LLC now owns 11,829 shares of the medical equipment provider's stock valued at $1,057,000 after purchasing an additional 561 shares in the last quarter. U.S. Capital Wealth Advisors LLC raised its holdings in Boston Scientific by 28.6% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 3,723 shares of the medical equipment provider's stock worth $333,000 after purchasing an additional 829 shares during the period. Finally, Stratos Wealth Partners LTD. raised its holdings in Boston Scientific by 136.1% in the 4th quarter. Stratos Wealth Partners LTD. now owns 23,590 shares of the medical equipment provider's stock worth $2,107,000 after purchasing an additional 13,597 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,572 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the sale, the executive vice president now directly owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the transaction, the senior vice president now owns 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 411,970 shares of company stock worth $42,406,693. Insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.8%

Shares of BSX stock traded down $0.79 on Friday, hitting $102.04. 9,114,389 shares of the stock traded hands, compared to its average volume of 6,465,530. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17. The firm's 50-day moving average price is $100.49 and its two-hundred day moving average price is $98.43. The stock has a market capitalization of $150.96 billion, a PE ratio of 81.63, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Boston Scientific's revenue was up 20.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.56 EPS. As a group, analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

BSX has been the topic of several research analyst reports. Barclays raised their price objective on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Truist Financial boosted their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a report on Thursday, April 24th. Royal Bank of Canada increased their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Finally, Argus set a $130.00 target price on shares of Boston Scientific in a research report on Tuesday, February 18th. Twenty-one equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $116.00.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.